Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0015674 (
chronic fatigue syndrome
)
2,978
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Patient-reported outcome monitoring with clinical feedback systems (PRO/
CFS
) has been employed in many disease states to measure and improve health-related quality of life (HRQOL). Exploring the role of PRO/
CFS
in treatment for obesity may prove valuable. Systematic reviews were summarized to determine the effectiveness of PRO/
CFS
on HRQOL in any disease area. Primary studies evaluating the effect of PRO/
CFS
on HRQOL in treatment for obesity were also considered for inclusion. Systematic searches were performed in The Cochrane Library, PROSPERO, Epistemonikos,
HTA
, DARE, CINAHL, Medline, Embase, PsycINFO, BMJ Clinical Evidence, PDQ-Evidence and PubPsych. Two reviewers independently screened references until final inclusion and critically appraised included reviews using PRISMA checklist. Five systematic reviews and no primary studies met inclusion criteria. Although results were inconsistent, effectiveness of PRO/
CFS
on HRQOL was demonstrated in some diseases/treatments (e.g. psychiatric treatment; symptom burden in cancer treatment). No trials using PRO/
CFS
in treatment for obesity were identified. In some trials, PRO/
CFS
was not fully integrated into consultations, thereby PRO/
CFS
was not extensively studied. General effectiveness of PRO/
CFS
on HRQOL is inconclusive due to heterogeneous and statistically insignificant findings, and lack of stringency in conceptualization and execution of PRO/
CFS
. There are no data relevant to treatment for obesity. Future studies should use rigorous methodology to examine the effectiveness of PRO/
CFS
in treatment for obesity.
...
PMID:A review of systematic reviews on the effects of patient-reported outcome monitoring with clinical feedback systems on health-related quality of life-implications for a novel technology in obesity treatment. 3020 66